Ignite Creation Date:
2025-12-24 @ 10:48 PM
Ignite Modification Date:
2025-12-25 @ 8:17 PM
Study NCT ID:
NCT00721669
Status:
COMPLETED
Last Update Posted:
2013-09-13
First Post:
2008-07-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
Sponsor:
ImmunoGen, Inc.
Organization:
Study Overview
Official Title:
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective is to evaluate the safety and PK of IMGN388
Detailed Description:
The secondary objectives are to assess the pharmacodynamics, immunogenicity, and tumor response of IMGN388 administered as an IV infusion once every three weeks in patients with solid tumors
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: